



Two Key Clinical Appointments to Impression's Medical Advisory Board

Highlights:

- Dr Rondhir Jithoo is a leading neurosurgeon based at the Alfred hospital in Melbourne, Victoria. He
 is also a research fellow at the National Trauma Research Institute, a partnership between Alfred
 Health and Monash University
- Dr Simon Hinckfuss is a leading periodontal specialist who is an experienced clinician, educator, researcher and celebrity TV dental specialist
- These appointments add clinical expertise and depth to Impression's Medical Advisory Board that
 is led by medicinal cannabis expert, specialist anaesthetist and CEO of Cannvalate Pty Ltd, Dr Sud
 Agarwal
- Medical Board advisors will assist with all facets of the clinical trials, product development, procuring funding grants and presenting research findings at conferences/clinical meetings and assisting with research documentation
- Discussions are underway to expand the Medical Advisory Board with other key opinion leaders relevant to Impression's Sleep Apnoea and TMJ Disorder medicinal cannabis development activities.

Impression Healthcare Limited ('Impression', 'IHL' or the 'Company'), developer of four unique medicinal cannabis products, owner of INCANNEX[™] cannabis oils and oral devices manufacturer, has appointed two leading medical experts to its Medical Advisory Board, overseen by Dr Sud Agarwal.

Dr Ronjith Jithoo and Dr Simon Hinckfuss are key opinion leaders in their respective fields of Traumatic Brain Injuries ('TBI') and Periodontal (gum/gingivitis) Disease. Both advisors will formally commence on the 1st of September for an initial term of two years to assist with; all facets of the TBI and periodontitis clinical trials, procuring funding grants, product development, presenting research findings at conferences/clinical meetings and assisting with research documentation.

Chief Medical Officer and non-executive director of Impression healthcare, Dr Sud Agarwal said; "Dr Jithoo and Dr Hinckfuss are globally renowned experts within their respective clinical fields. They both bring extensive expertise to assist with designing and researching the traumatic brain injury and periodontitis clinical assets. As key opinion leaders within their craft groups, the significant authority and gravitas they hold will underpin our strategy to deliver unique, IP-defendable products to the marketplace".

Dr Rondhir (Ron) Jithoo MBChB FRACS (Neuro) FCS(SA), FICS

Dr Rondhir Jithoo is a consultant neurosurgeon at the Alfred Hospital in Melbourne, Victoria. He is a research fellow at the National Trauma Research Institute (NTRI), established in 2003 by partnership





institutions Alfred Health and Monash University, and a Traumatic Brain Injury researcher and clinician.

Prior to his current roles, Dr Jithoo was deputy chair of Neurosciences at Epworth Hospital, former Acting Head of Neurosurgery the Alfred Hospital and a reviewer for the Journal of Clinical Neuroscience.

Dr Jithoo obtained his medical degree from the Nelson Mandella School of Medicine at the University of Natal, in Durban, South Africa; receiving his Degree with the team's commendation. He then undertook neurosurgical training in South Africa at Wentworth Hospital, and obtained the Fellowship of the College of Surgeons in Neurosurgery in 2001. He subsequently undertook further training in Australia, culminating in the award of the Australasian Fellowship in Neurosurgery by examination in 2004.

Dr Simon Hinckfuss BDSc DCD (Melb) Cert Perio MS (Minn, USA)

Dr Simon Hinckfuss is a high-profile specialist periodontist, focusing on the management of periodontitis, cosmetic periodontal plastic surgery and the surgical placement of dental implants. After attending dental school at the University of Melbourne in 1995, Dr Hinckfuss went on to complete a Doctor of Clinical Dentistry in Prosthodontics as well as specialist training in periodontics, including extensive surgical training in implant dentistry.

Dr Hinckfuss has an established specialist periodontology practice in Collins St, Melbourne. He also regularly lectures at educational institutions internationally. He is the first and only dentist in Australia to be dual registered with the Dental Board of Australia as a specialist in the fields of both prosthodontics and periodontology. In 2011 he was admitted as a Diplomat of the American Board of Periodontology.

As a senior clinician, educator, gingivitis researcher and TV celebrity dentist, he is uniquely positioned to lead the design and testing of the INCANNEXTM cannabinoid toothpaste and mouthwash clinical assets.

ENDS



Date: 29th August 2019 ASX Announcement (ASX: IHL)

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited (IHL.ASX) is undertaking four clinical trials investigating the use of uniquely formulated medicinal cannabis products for the treatment of Obstructive Sleep Apnoea, Traumatic Brain Injury/Concussion, Periodontitis (Gum Disease) and Temporomandibular Joint Disorder. Each indication represents major global markets.

IHL has its Australian licenses in place to import, export and distribute cannabis products and has launched a line of EU GMP-approved CBD oil products under the brand, "IncannexTM". IncannexTM oils may be sold under IHL's product supply and distribution agreement with Cannvalate Pty Ltd – the largest network of cannabis medicine prescribers in Australia.

Impression also has a collaboration and "first right of refusal" agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Incorporated and a license agreement with Resolution Chemicals for the production and distribution of Dronabinol in the USA, Canada, Australia and New Zealand.

Providing growing revenues to the Company; Impression continues to build its customised oral devices manufacturing business both direct-to-the-consumer and via the Company's growing B2B preferred practitioner network.

Investors: investors@impression.healthcare

Website: www.impression.healthcare